Free Republic

Phase 3 trial results by biotech company Regeneron showed its new drug provides long-term protection against COVID-19, KTLA sister station KRON reported. A single dose of the antibody cocktail reduced the risk of contracting COVID-19 by 81.6% during months 2-8, according to results released Monday. Previously published results already showed its effectiveness within one month of getting the injection. Regeneron said none of the participants who were injected with a single dose of the ‘REGEN-COV’ antibody cocktail were hospitalized with COVID-19 during the eight-month trial run in collaboration with the National Institute of Allergy and Infectious Diseases. Meanwhile, six people...

Beloved young relative has covid. There is no Regeneron in the state. Offered Sotromab. Feedback? Never heard of it.

Huntsville Memorial Hospital is the latest to start offering COVID-19 monoclonal antibody infusion treatments. As the number of COVID-19 hospitalizations continues to rise across the state, more treatments and resources are becoming available for those who contract the virus. Dr. Sujesh Pillai is the chief of staff for Huntsville Memorial. He says they’ve administered a little over 50 infusions in the last two weeks, and only one person had to be admitted to the hospital. “When you get the infusion treatment, it’s a one-hour IV infusion that we do in the hospital. You’re not admitted. You go home right after...

**HERE'S WHAT WAS SHARED IN ANOTHER MEWE FORUM** : **This is very useful Life Saving information for those in the USA.** *Monoclonal Antibodies are one of the best therapies for those with Covid. President Trump himself was injected with Regeneron monoclonals and was released from Walter Reed Hospital in a few days, ready to resume his job.* *Here are the Hospitals in the USA that have received shipments of monoclonal antibody therapeutics.* *Punch in your city or ZIP Code to see if a hospital near you offers this therapeutic. Apparently, this therapeutic is available in all 50 states.* https://protect-public.hhs.gov/pages/therapeutics-distribution#distribution-locations

The UK RECOVERY trial investigators recently disclosed that Regeneron’s REGEN-COV, a pair of monoclonal antibodies, actually reduced the risk of death by 20% in patients hospitalized with COVID-19 who failed to sustain their own immune response. According to the company’s press release, this monoclonal antibody cocktail represents the first antibody treatment that improved survival in patients hospitalized with COVID-19. The company will not only share this data with regulatory authorities immediately but will also seek to expand its U.S. EUA to include appropriate hospitalized patients.TrialSite provides a brief summary breakdown of this most recent information generated by the UK RECOVERY...

The U.S. Food and Drug Administration has expanded the emergency use authorization of Regeneron Pharmaceuticals Inc's (REGN.O) COVID-19 antibody cocktail, enabling its use as a preventive treatment for the illness in certain people.

“With more than 60,000 Americans continuing to be diagnosed with COVID-19 every day, the REGEN-COV antibody cocktail may help provide immediate protection to unvaccinated people who are exposed to the virus,” Dr. George Yancopoulos, president and chief scientific officer at Regeneron, said in a press release.

Regeneron's cocktail, a mixture of two drugs, imitates antibodies that the body generates when fighting the coronavirus in order to boost the immune system The antibody treatment was authorized by the FDA to treat mild to moderate cases of COVID-19 in November Half a group of 4,500 mild-to-moderate COVID-19 patients at high risk of severe illness were given one of two doses of the drugs Both doses were found to reduce the risk of hospitalization or death by about 70% compared to a placebo Recovery time was also shortened, with symptoms only lasting about 10 days in the cocktail group...